Autoimmune Diseases  >>  Extavia (IFN-β-1b)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Extavia (IFN-β-1b) / Novartis
EPOC, NCT01216072: A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

Checkmark CMSC-ACTRIMS 2013: Multiple sclerosis (EPOC)
Jun 2013 - Jun 2013: CMSC-ACTRIMS 2013: Multiple sclerosis (EPOC)
Checkmark EPOC
May 2013 - May 2013: EPOC
Checkmark ENS 2013: Multiple sclerosis (EPOC)
More
Completed
4
1053
US, Canada
Fingolimod, GILENYA™, Standard MS DMTs, Avonex®,, Copaxone®,, Rebif®,, Betaseron®,, Extavia®
Novartis Pharmaceuticals
Relapsing Forms of Multiple Sclerosis
08/12
08/12
EPOC, NCT01317004 / 2010-024017-31: Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change

Completed
4
61
Europe
Fingolimod, GILENYA™, Standard MS DMT, Avonex®,, Copaxone®,, Rebif®,, Betaferon®,, Extavia®
Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
06/14
06/14

Download Options